ACEA Biosciences
2002
FOUNDED
M&A
STATUS
201-300
EMPLOYEES
M&A
LATEST DEAL TYPE
$250M
LATEST DEAL AMOUNT
Description
Developer of cell analysis instruments designed to help in life science research and clinical diagnostics. The company's instruments use microelectrodes in automated high-throughput plate formats to offer real time cell analysis, enabling doctors to monitor cell proliferation, cell size, cell-substrate attachment quality and cell invasion easily.
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Devices and Supplies
Other Industries
Biotechnology
Other Healthcare Technology Systems
Parent Company
Primary Office
- 6779 Mesa Ridge Road
- Suite 100
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore ACEA Biosciences’s full profile, request a free trial.
ACEA Biosciences Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 14-Nov-2018 | $250M | 000.00 | 00000 | Completed | Clinical Trials - Phase 1 |
| 6. Later Stage VC (Series E) | 06-Nov-2015 | 0000 | 000.00 | 00000 | Completed | Clinical Trials - Phase 1 |
| 5. Grant | 03-Jul-2013 | 000.00 | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series D) | 10-Sep-2007 | 00.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 3. Later Stage VC (Series C) | 00.000 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series B) | $1.85M | $4.15M | 000.00 | Completed | ||
| 1. Early Stage VC (Series A) | $2.3M | $2.3M | 00.000 | Completed |
ACEA Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series D | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series C | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series B | 1,589,690 | $0.001000 | 4% | $1.16 | $1.16 | 1x | $1.16 | 7.98% |
| Series A | 3,199,414 | $0.001000 | 4% | $0.95 | $0.95 | 1x | $0.95 | 16.06% |
ACEA Biosciences Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Lilly Asia Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Qiming Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| U.S. Environmental Protection Agency | Other | 000 0000 | 000000 0 |
ACEA Biosciences Executive Team (10)
2 Former Executives
You’re viewing 5 of 10 executives. Get the full list »ACEA Biosciences Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Feng Lin | ACEA Biosciences | Co-Founder & Co-Chairman | 000 0000 | |
| Lin Jixun | ACEA Biosciences | Co-Founder & Co-Chairman | 000 0000 |